Benzoxazole derivatives as new VEGFR-2 inhibitors and apoptosis inducers: design, synthesis, in silico studies, and antiproliferative evaluation

References

• Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 2019;16:589–604.
   PubMed Web of Science ®Google Scholar
• Paci A, Veal G, Bardin C, et al. Review of therapeutic drug monitoring of anticancer drugs part 1–cytotoxics. Euro J Cancer 2014;50:2010–9.
   PubMed Web of Science ®Google Scholar
• Abdelgawad MA, El-Adl K, El-Hddad SS, et al. Design, molecular docking, synthesis, anticancer and anti-hyperglycemic assessments of thiazolidine-2, 4-diones Bearing Sulfonylthiourea Moieties as Potent VEGFR-2 Inhibitors and PPARγ Agonists. Pharmaceuticals 2022;15:226.
   Web of Science ®Google Scholar
• Chen H, Kovar J, Sissons S, et al. A cell-based immunocytochemical assay for monitoring kinase signaling pathways and drug efficacy. Anal Biochem 2005;338:136–42.
   PubMed Web of Science ®Google Scholar
• Traxler P, Furet P. Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. Pharmacol Therapeutics 1999;82:195–206.
   PubMed Web of Science ®Google Scholar
• Kang D, Pang X, Lian W, et al. Discovery of VEGFR2 inhibitors by integrating naïve Bayesian classification, molecular docking and drug screening approaches. RSC Adv 2018;8:5286–97.
   PubMed Web of Science ®Google Scholar
• El-Helby A-GA, Sakr H, Ayyad RR, et al. Design, synthesis, molecular modeling, in vivo studies and anticancer activity evaluation of new phthalazine derivatives as potential DNA intercalators and topoisomerase II inhibitors. Bioorg Chem 2020;103:104233.
   PubMed Web of Science ®Google Scholar
• Veeravagu A, Hsu AR, Cai W, et al. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy. Recent Patents Anti Cancer Drug Disc 2007;2:59–71.
   PubMed Web of Science ®Google Scholar
• Eissa IH, El-Helby A-GA, Mahdy HA, et al. Discovery of new quinazolin-4 (3H)-ones as VEGFR-2 inhibitors: design, synthesis, and anti-proliferative evaluation. Bioorg Chem 2020;105:104380.
   PubMed Web of Science ®Google Scholar
• Ran F, Li W, Qin Y, et al. Inhibition of vascular smooth muscle and cancer cell proliferation by new VEGFR inhibitors and their immunomodulator effect: design, synthesis, and biological evaluation. Oxid Med Cellular Longevity 2021;2021:1–21.
   Web of Science ®Google Scholar
• Claesson‐Welsh L, Welsh M. VEGFA and tumour angiogenesis. J Intern Med 2013;273:114–27.
   PubMed Web of Science ®Google Scholar
• El-Metwally SA, Abou-El-Regal MM, Eissa IH, et al. Discovery of thieno [2, 3-d] pyrimidine-based derivatives as potent VEGFR-2 kinase inhibitors and anti-cancer agents. Bioorg Chem 2021;112:104947.
   PubMed Web of Science ®Google Scholar
• Abbass EM, Khalil AK, Mohamed MM, et al. Design, efficient synthesis, docking studies, and anticancer evaluation of new quinoxalines as potential intercalative Topo II inhibitors and apoptosis inducers. Bioorg Chem 2020;104:104255.
   PubMed Web of Science ®Google Scholar
• Ghorab MM, Alsaid MS, Soliman AM, Ragab FA. VEGFR-2 inhibitors and apoptosis inducers: synthesis and molecular design of new benzo [g] quinazolin bearing benzenesulfonamide moiety. J Enzy Inhib Med Chem 2017;32:893–907.
   PubMed Web of Science ®Google Scholar
• Lee K, Jeong K-W, Lee Y, et al. Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors. Euro J Med Chem 2010;45:5420–7.
   PubMed Web of Science ®Google Scholar
• Machado VA, Peixoto D, Costa R, et al. Synthesis, antiangiogenesis evaluation and molecular docking studies of 1-aryl-3-[(thieno [3, 2-b] pyridin-7-ylthio) phenyl] ureas: Discovery of a new substitution pattern for type II VEGFR-2 Tyr kinase inhibitors. Bioorg Med Chem 2015;23:6497–509.
   PubMed Web of Science ®Google Scholar
• Garofalo A, Goossens L, Six P, et al. Impact of aryloxy-linked quinazolines: A novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett 2011;21:2106–12.
   PubMedGoogle Scholar
• Elkady H, Elwan A, El-Mahdy HA, et al. New benzoxazole derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: design, synthesis, anti-proliferative evaluation, flowcytometric analysis, and in silico studies. J Enzy Inhib Med Chem 2022;37:397–410.
   PubMed Web of Science ®Google Scholar
• Papaetis GS, Syrigos KN. Sunitinib. Bio Drugs 2009;23:377–89.
   Google Scholar
• Soria J-C, DeBraud F, Bahleda R, et al. Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors. Ann Oncol 2014;25:2244–51.
   PubMed Web of Science ®Google Scholar
• Mahdy HA, Ibrahim MK, Metwaly AM, et al. Design, synthesis, molecular modeling, in vivo studies and anticancer evaluation of quinazolin-4 (3H)-one derivatives as potential VEGFR-2 inhibitors and apoptosis inducers. Bioorg Chem 2020;94:103422.
   PubMed Web of Science ®Google Scholar
• Alanazi MM, Elkady H, Alsaif NA, et al. New quinoxaline-based VEGFR-2 inhibitors: design, synthesis, and antiproliferative evaluation with in silico docking, ADMET, toxicity, and DFT studies. RSC Adv 2021;11:30315–28.
   PubMed Web of Science ®Google Scholar
• Alanazi MM, Eissa IH, Alsaif NA, et al. Design, synthesis, docking, ADMET studies, and anticancer evaluation of new 3-methylquinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers. J Enzy Inhib Med Chem 2021;36:1760–82.
   PubMed Web of Science ®Google Scholar
• Alanazi MM, Elkady H, Alsaif NA, et al. Discovery of new quinoxaline-based derivatives as anticancer agents and potent VEGFR-2 inhibitors: Design, synthesis, and in silico study. J Mol Struc 2022;1253:132220.
   Web of Science ®Google Scholar
• El-Zahabi MA, Sakr H, El-Adl K, et al. Design, synthesis, and biological evaluation of new challenging thalidomide analogs as potential anticancer immunomodulatory agents. Bioorg Chem 2020;104:104218.
   PubMed Web of Science ®Google Scholar
• Eldehna WM, Abo-Ashour MF, Ibrahim HS, et al. Novel [(3-indolylmethylene) hydrazono] indolin-2-ones as apoptotic anti-proliferative agents: design, synthesis and in vitro biological evaluation. J Enzy Inhib Med Chem 2018;33:686–700.
   PubMed Web of Science ®Google Scholar
• Al-Rashood ST, Hamed AR, Hassan GS, et al. Antitumor properties of certain spirooxindoles towards hepatocellular carcinoma endowed with antioxidant activity. J Enzy Inhib Med Chem 2020;35:831–9.
   PubMed Web of Science ®Google Scholar
• El-Helby A-GA, Ayyad RR, El-Adl K, Elkady H. Phthalazine-1, 4-dione derivatives as non-competitive AMPA receptor antagonists: design, synthesis, anticonvulsant evaluation, ADMET profile and molecular docking. Mol Div 2019;23:283–98.
   PubMed Web of Science ®Google Scholar
• El‐Helby AGA, Ayyad RR, Zayed MF, et al. Design, synthesis, in silico ADMET profile and GABA‐A docking of novel phthalazines as potent anticonvulsants. Archiv Der Pharmazie 2019;352:1800387.
   Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Del Rev 1997;23:3–25.
   Web of Science ®Google Scholar
• Veber DF, Johnson SR, Cheng H-Y, et al. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 2002;45:2615–23.
   PubMed Web of Science ®Google Scholar
• Alsaif NA, Taghour MS, Alanazi MM, et al. Discovery of new VEGFR-2 inhibitors based on bis ([1, 2, 4] triazolo)[4, 3-a: 3', 4'-c] quinoxaline derivatives as anticancer agents and apoptosis inducers. J Enzy Inhib Med Chem 2021;36:1093–114.
   PubMed Web of Science ®Google Scholar
• Alsaif NA, Dahab MA, Alanazi MM, et al. New quinoxaline derivatives as VEGFR-2 inhibitors with anticancer and apoptotic activity: design, molecular modeling, and synthesis. Bioorg Chem 2021;110:104807.
   PubMed Web of Science ®Google Scholar
• Wang J, Lenardo MJ. Roles of caspases in apoptosis, development, and cytokine maturation revealed by homozygous gene deficiencies. J Cell Sci 2000;113:753–7.
   PubMed Web of Science ®Google Scholar
• Eldehna WM, Hassan GS, Al-Rashood ST, et al. m. chemistry, Synthesis and in vitro anticancer activity of certain novel 1-(2-methyl-6-arylpyridin-3-yl)-3-phenylureas as apoptosis-inducing agents. J Enzyme Inhib Med Chem 2019;34:322–32.
   PubMed Web of Science ®Google Scholar
• Lo KK-W, Lee TK-M, Lau JS-Y, et al. Luminescent biological probes derived from ruthenium (II) estradiol polypyridine complexes. Inorg Chem 2008;47:200–8.
   PubMed Web of Science ®Google Scholar
• Sabt A, Abdelhafez OM, El-Haggar RS, et al. Novel coumarin-6-sulfonamides as apoptotic anti-proliferative agents: synthesis, in vitro biological evaluation, and QSAR studies. J Enzyme Inhib Med Chem 2018;33:1095–107.
   PubMed Web of Science ®Google Scholar
• Balah A, Ezzat O, Akool E-S. Vitamin E inhibits cyclosporin A-induced CTGF and TIMP-1 expression by repressing ROS-mediated activation of TGF-β/Smad signaling pathway in rat liver. Inter Immunopharmacol 2018;65:493–502.
   PubMed Web of Science ®Google Scholar
• Aborehab NM, Elnagar MR, Waly NE. Gallic acid potentiates the apoptotic effect of paclitaxel and carboplatin via overexpression of Bax and P53 on the MCF‐7 human breast cancer cell line. J Biochem Mol Toxicol 2021; 35:e22638.
   PubMed Web of Science ®Google Scholar
• Elnagar MR, Walls AB, Helal GK, et al. Functional characterization of α7 nicotinic acetylcholine and NMDA receptor signaling in SH-SY5Y neuroblastoma cells in an ERK phosphorylation assay. Euro J Pharmacol 2018;826:106–13.
   PubMed Web of Science ®Google Scholar
• Belal A, Elanany MA, Santali EY, et al. Screening a panel of topical ophthalmic medications against MMP-2 and MMP-9 to investigate their potential in keratoconus management. Molecules 2022;27:3584.
   PubMed Web of Science ®Google Scholar
• Elkaeed EB, Youssef FS, Eissa IH, et al. Multi-step in silico discovery of natural drugs against COVID-19 targeting main protease. Inter J Mol Sci 2022;23:6912.
   PubMed Web of Science ®Google Scholar
• Elkaeed EB, Elkady H, Belal A, et al. Multi-phase in silico discovery of potential SARS-CoV-2 RNA-dependent RNA polymerase inhibitors among 3009 clinical and FDA-approved related drugs. Processes 2022;10:530.
   Web of Science ®Google Scholar
• Abdallah AE, Alesawy MS, Eissa SI, et al. Design and synthesis of new 4-(2-nitrophenoxy) benzamide derivatives as potential antiviral agents: Molecular modeling and in vitro antiviral screening. N J Chem 2021;45:16557–71.
   Web of Science ®Google Scholar
• Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 2017;7:42717.
   PubMed Web of Science ®Google Scholar
• Daina A, Michielin O, Zoete V. iLOGP: a simple, robust, and efficient description of n-octanol/water partition coefficient for drug design using the GB/SA approach. J Chem Inform Model 2014;54:3284–301.
   PubMed Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2012;64:4–17.
   Web of Science ®Google Scholar